Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
Healthcare
$0.50 +3.03%
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
52W Low $0.56High $1.51
Volume 0.38M
Average 1.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$27.60M
FY 2025 · Annual
Investing Cash Flow
-$8,232.00
FY 2025 · Annual
Financing Cash Flow
$19.37M
FY 2025 · Annual
+192.0% YoYCash Flow Statement
CAD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.3M) | (24.84M) | (27.75M) | (31.71M) | (39.46M) |
| Depreciation & Amortization | 452.07K | 392K | 403K | 424K | 96.05K |
| Deferred Income Tax | 408.56K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.83M | 2.38M | 2.07M | 2.72M | 4.26M |
| Change in Working Capital | (907.99K) | 391K | 1.77M | 3.54M | 1.62M |
| Accounts Receivables | (776.39K) | 345K | 506K | (53K) | 4.03M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (131.59K) | 46K | 1.26M | 3.59M | (2.41M) |
| Other Non-Cash Items | 91.73K | (1.68M) | (4.93M) | (1.94M) | 5.89M |
| Operating Cash Flow | (22.43M) | (23.36M) | (28.45M) | (26.97M) | (27.6M) |
| Capital Expenditures | (285.95K) | (55K) | (8K) | (239K) | (8.23K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.35M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 20.23M | 0 | 0 |
| Other Investing Activities | 0 | (20.35K) | 0 | 0 | 0 |
| Investing Cash Flow | (285.95K) | (20.4M) | 20.22M | (239K) | (8.23K) |
| Debt Repayment | (366K) | (381K) | (407K) | (348K) | 0 |
| Common Stock Issued | 32.91M | 12.57M | 31.62M | 6.92M | 19.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 469.68K | 12K | 781K | 65K | (37.05K) |
| Financing Cash Flow | 33.02M | 12.21M | 31.99M | 6.64M | 19.37M |
| Effect of Forex Changes | (253.25K) | 1.96M | (522K) | 1.6M | 166.03K |
| Net Change in Cash | 10.04M | (29.6M) | 23.25M | (18.97M) | (8.06M) |
| Free Cash Flow | (22.72M) | (23.41M) | (28.46M) | (27.21M) | (27.6M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.5M
+ D&A$96.0K
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
+ Working Capital$1.6M
+ Other Non-Cash$5.9M
= Operating Cash Flow-$27.6M
- Capex-$8.2K
= Free Cash Flow-$27.6M
Analysis
FY2025 free cash flow is -$27.6M. FCF conversion is 69.9% of net income. Operating cash flow was -$27.6M, with capex of -$8.2K. The largest bridge item is Other Non-Cash at $5.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 20, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 8-K | Current report | Oct 13, 2026 | |
| DEFA14A | DEFA14A filing | Oct 6, 2026 | |
| DEF 14A | DEF 14A filing | Oct 6, 2026 |
Does ONCY generate free cash flow?
Oncolytics Biotech Inc. (ONCY) generated -$27.60M of free cash flow in fiscal 2025.
How much operating cash flow does ONCY produce?
Operating cash flow was -$27.60M, before capital expenditures of $8,232.00.
Continue the stock analysis
Jump to another research area for this company.